MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
Article content
Article content
'Brandi joins MindMed at a pivotal moment for the company, bringing with her a powerful combination of financial acumen, strategic vision, and deep biotech sector expertise,' said Rob Barrow, Chief Executive Officer of MindMed. 'Her proven track record leading public companies through transformative milestones, including initial public offerings (IPO), business development and investor engagement makes her a valuable addition to our organization. As we accelerate toward the potential commercialization of MM120 ODT, her understanding of the healthcare landscape and executional strength will be instrumental in advancing our strategy, driving growth, and delivering long-term value for both patients and shareholders.'
Article content
'MindMed is leading a true paradigm shift in mental health treatment, and I'm excited to collaborate with a team renowned for its exceptional depth and breadth of experience in drug development,' said Ms. Roberts. 'With MM120 ODT, the company is advancing a potential breakthrough for the millions of people in the U.S. suffering from GAD and MDD. Joining MindMed is an extraordinary opportunity to continue building a robust financial infrastructure that matches the strength of the Company's science; delivering a comprehensive strategic financial vision built to support innovation, agility, and access with the goal of helping patients and making a meaningful impact in addressing the mental health crisis.'
Article content
Ms. Roberts has more than 25 years of financial leadership experience within the life sciences industry. Most recently, she served as CFO and Executive Vice President of Longboard Pharmaceuticals, where she helped lead the company through its IPO, multiple financings, and ultimately, its $2.6 billion acquisition by Lundbeck in 2024. Throughout her career, Ms. Roberts has played pivotal roles in scaling operations, supporting clinical development, and managing investor relations with leading investors, funds, and analysts. She has held CFO roles at Lineage Cell Therapeutics, REVA Medical, and Mast Therapeutics, and senior finance positions at Alphatec Spine, Inc., Artes Medical, Inc., Stratagene Corporation, and Pfizer, Inc. Ms. Roberts received her MBA from the University of San Diego and her B.S. degree in business administration in Accounting and Finance from the University of Arizona. She is a Certified Public Accountant in the State of California and currently serves on the board of advisors for Life Science Cares San Diego and the board for the Association of Bioscience Financial Officers Southwest chapter.
Article content
In connection with her appointment as Chief Financial Officer on June 2, 2025, MindMed will grant Ms. Roberts on such date inducement awards consisting of (i) an option to purchase 500,000 common shares of the Company (the 'Option') and (ii) 125,000 performance share units (the 'PSUs') (assuming achievement at target levels of performance) that, if earned, will be settled in MindMed common shares upon vesting. The Option will have an exercise price equal to the closing price of MindMed's common shares on May 30, 2025, the last trading day on which MindMed's common shares will trade prior to the date of the grant and will vest over a four-year period with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments over the three-year period thereafter, subject to her continued employment. The PSUs will vest on the third anniversary of the grant date, subject to continued service through the vesting date. Actual earned PSUs can range from 0%-200% of the target number of PSUs and will be based on the achievement of certain performance metrics as measured at the end of the three-year performance period.
Article content
The inducement awards to Ms. Roberts will be granted as a material inducement to her entering into employment with MindMed and were approved by MindMed's Compensation Committee on May 21, 2025, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The awards were granted outside MindMed's equity incentive plans.
Article content
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
Article content
Forward-Looking Statements
Article content
Certain statements in this news release related to the Company constitute 'forward-looking information' within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'will', 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe', 'potential' or 'continue', or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company's beliefs regarding potential benefits of MM120 ODT for GAD and MDD; the size of the addressable market for MM120 ODT for treatment of GAD and MDD; the Company's plans to appoint Ms. Roberts as CFO effective June 2, 2025, and to grant her inducements awards in connection therewith. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; ability to maintain effective patent rights and other intellectual property protection; as well as those risk factors discussed or referred to herein and the risks, uncertainties and other factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 under headings such as 'Special Note Regarding Forward-Looking Statements,' and 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
39 minutes ago
- CTV News
‘We're done': Union president on Air Canada flight attendants refusing back to work order
Video CUPE's Air Canada Component President Wesley Lesosky says that the union is 'not willing' to accept the back-to-work order.
CTV News
an hour ago
- CTV News
Air Canada flight attendants continue strike despite order to return, airline delays restart
CUPE's Air Canada Component President Wesley Lesosky says that the union is 'not willing' to accept the back-to-work order. Air Canada flight attendants remained on strike on Sunday past the deadline in a government-backed labor board's order to return to work, causing the country's biggest airline to delay restarting operations. The Canadian Union of Public Employees said in a statement that members would remain on strike and invited Air Canada back to the table to 'negotiate a fair deal,' calling the order to end its strike unconstitutional. The airline said it would delay plans to restart operations from Sunday until Monday evening. On Saturday, Prime Minister Mark Carney's Liberal government moved to end the strike by more than 10,000 flight attendants by asking the Canada Industrial Relations Board to order binding arbitration. The CIRB issued the order, which Air Canada had sought, and unionized flight attendants opposed. The Canada Labour Code gives the government the power to ask the CIRB to impose binding arbitration in the interest of protecting the economy. The government's options to end the strike now include asking courts to enforce the order to return to work and seeking an expedited hearing. The minority government could also try to pass legislation that would need the support of political rivals and approval in both houses of parliament, which is on break until September 15. The government did not respond to requests for comment. 'The federal government has entrusted a board to administer these rules in the Canadian Labor Code, and if you defy them, you are transgressing and essentially violating the law,' said Rafael Gomez, a professor of employment relations at the University of Toronto. The government, under former Prime Minister Justin Trudeau, intervened last year to head off rail and dock strikes that threatened to cripple the economy, but it is unusual for a union to defy a CIRB order. Flights grounded, passengers stranded Air Canada flight attendants walked off the job on Saturday for the first time since 1985, after months of negotiations over a new contract. Air Canada had said it planned to resume flights on Sunday evening, following the expected end of the strike that caused the suspension of around 700 daily flights on Saturday, stranding more than 100,000 passengers. The union called a decision by the CIRB chair Maryse Tremblay to not recuse herself from handling the case a 'staggering conflict of interest,' since she had worked as a senior counsel for Air Canada in the past. According to Tremblay's LinkedIn profile, she served as Air Canada's counsel from 1998 to 2004. The CIRB did not respond to a request for comment. Other unions joined the flight attendants' picket line in solidarity in Toronto on Sunday. 'They are in support here today because they are seeing our rights being eroded,' said Natasha Stea, an Air Canada flight attendant and local union president. Air Canada had started canceling flights on Thursday in anticipation of the stoppage. Travelers at Toronto Pearson International Airport said they were confused about whether their flights would resume or Air Canada would make alternative arrangements. 'We are kind of left to figure it out for ourselves and fend for ourselves with no recourse or options provided by Air Canada at this time,' said Elizabeth Fourney of Vancouver. The most contentious issue has been the union's demand for compensation for time spent on the ground between flights and when helping passengers board. Attendants are largely paid only when their plane is moving. CUPE had pushed for a negotiated solution, saying binding arbitration would take pressure off the airline. Air Canada said on Sunday that the CIRB had ordered the terms of the collective agreement between the union and the airline that expired on March 31 be extended until a new agreement can be reached. (Reporting by Allison Lampert in Montreal and Rishabh Jaiswal in Bengaluru; Editing by Tomasz Janowski, Kirsten Donovan, Rod Nickel)
Globe and Mail
an hour ago
- Globe and Mail
BWEN Investors Have Opportunity to Join Broadwind, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Broadwind, Inc. ('Broadwind' or 'the Company') (NASDAQ: BWEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Broadwind announced its Q2 2025 financial results on August 12, 2025. The Company missed consensus estimates for earnings per share, and suspended its full-year 2025 guidance. Based on this news, shares of Broadwind fell by more than 14.4% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
